Zobrazeno 1 - 10
of 65
pro vyhledávání: '"Anna Mae Diehl"'
Autor:
Sihyung Wang, Youngmi Jung, Jeongeun Hyun, Matthew Friedersdorf, Seh-Hoon Oh, Jieun Kim, Richard T. Premont, Jack D. Keene, Anna Mae Diehl
Publikováno v:
Cellular Physiology and Biochemistry, Vol 48, Iss 3, Pp 1215-1229 (2018)
Background/Aims: Myofibroblasts (MF) derived from quiescent nonfibrogenic hepatic stellate cells (HSC) are the major sources of fibrous matrix in cirrhosis. Because many factors interact to regulate expansion and regression of MF-HSC populations, eff
Externí odkaz:
https://doaj.org/article/79865b208d884ea78ffe5ee0a26e1ad6
Autor:
Arun J. Sanyal, Stephen A. Williams, Joel E. Lavine, Brent A. Neuschwander-Tetri, Leigh Alexander, Rachel Ostroff, Hannah Biegel, Kris V. Kowdley, Naga Chalasani, Srinivasan Dasarathy, Anna Mae Diehl, Rohit Loomba, Bilal Hameed, Cynthia Behling, David E. Kleiner, Saul J. Karpen, Jessica Williams, Yi Jia, Katherine P. Yates, James Tonascia
Publikováno v:
Journal of hepatology, vol 78, iss 4
J Hepatol
J Hepatol
There is an unmet need for development of non-invasive tests for the diagnostic assessment and monitoring of nonalcoholic fatty liver disease (NAFLD).Using modified-aptamer proteomics, we assayed 5220 proteins in each of 2852 single serum samples fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b98d930021ee18e344ed6b8fc32118b5
https://escholarship.org/uc/item/0d9809np
https://escholarship.org/uc/item/0d9809np
Autor:
Rajesh Kumar Dutta, Seh-Hoon Oh, Wen-Hsuan Yang, Jen-Tsan Ashley Chi, Kuo Du, Anna Mae Diehl, Tianai Sun
Publikováno v:
Liver Int
Background & aims The outcome of liver injury is dictated by factors that control the accumulation of myofibroblastic (activated) hepatic stellate cells (MF-HSCs) but therapies that specifically block this process have not been discovered. We evaluat
Autor:
C. Stephen Djedjos, Raul Aguilar Schall, Zachary Goodman, B. Mccolgan, G. Mani Subramanian, Anna Mae Diehl, Nezam H. Afdhal, Andrew J. Muir, Jaime Bosch, Vlad Ratziu, Zobair M. Younossi, Manal F. Abdelmalek, Arun J. Sanyal, Stephen H. Caldwell, Mitchell L. Shiffman, Catherine Jia, John G. McHutchison, Stephen A. Harrison, Robert P. Myers
Publikováno v:
Hepatology
Progression of nonalcoholic steatohepatitis (NASH) is incompletely characterized. We analyzed data on longitudinal changes in liver histology, hepatic venous pressure gradient (HVPG), and serum markers of fibrosis in 475 patients with NASH with bridg
Autor:
Anna Mae Diehl, Nezam H. Afdhal, Andrew J. Muir, Jaime Bosch, G. Mani Subramanian, Zachary Goodman, Raul Aguilar Schall, Arun J. Sanyal, Stephen A. Harrison, Stephen H. Caldwell, B. Mccolgan, Maria Stepanova, Manal F. Abdelmalek, Robert P. Myers, Vlad Ratziu, Zobair M. Younossi, Mitchell L. Shiffman
Publikováno v:
Journal of Hepatology. 69:1365-1370
Although patients with cryptogenic cirrhosis have historically been considered as having "burnt-out" non-alcoholic steatohepatitis (NASH), some controversy remains. The aim of this study was to compare outcomes of patients with cryptogenic cirrhosis
Autor:
B. Mccolgan, Eric Lawitz, Anna Mae Diehl, Catherine Jia, Manal F. Abdelmalek, Jaime Bosch, Zobair M. Younossi, G. Mani Subramanian, Mitchell L. Shiffman, John G. McHutchison, Reem Ghalib, Nezam H. Afdhal, Don C. Rockey, Andrew J. Muir, Raul Aguilar Schall, Vlad Ratziu, Zachary Goodman, Stephen H. Caldwell, Arun J. Sanyal, Stephen A. Harrison, Robert P. Myers
Publikováno v:
Gastroenterology. 155:1140-1153
Background & Aims Lysyl oxidase-like 2 contributes to fibrogenesis by catalyzing cross-linkage of collagen. We evaluated the safety and efficacy of simtuzumab, a monoclonal antibody against lysyl oxidase-like 2, in two phase 2b trials of patients wit
Autor:
Sarah E. Kleinstein, David Goldstein, Cynthia A. Moylan, Cynthia D. Guy, Anna Mae Diehl, Manal F. Abdelmalek, Matthew Rein
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 2, Iss 9, Pp 1021-1029 (2018)
Hepatology Communications, Vol 2, Iss 9, Pp 1021-1029 (2018)
Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous disease with highly variable outcomes. Patients with simple steatosis typically experience a benign course, whereas those with more advanced liver injury, nonalcoholic steatohepatitis (NASH)
Autor:
Jeongeun Hyun, Anna Mae Diehl, Matthew B Friedersdorf, Youngmi Jung, Seh-Hoon Oh, Jack D. Keene, Richard T. Premont, Ji Eun Kim, Sihyung Wang
Publikováno v:
Cellular Physiology and Biochemistry, Vol 48, Iss 3, Pp 1215-1229 (2018)
Background/Aims: Myofibroblasts (MF) derived from quiescent nonfibrogenic hepatic stellate cells (HSC) are the major sources of fibrous matrix in cirrhosis. Because many factors interact to regulate expansion and regression of MF-HSC populations, eff
Publikováno v:
Critical Reviews in Biochemistry and Molecular Biology. 53:264-278
Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of obesity-associated liver diseases and it has become the major cause of cirrhosis in the Western world. The high prevalence of NAFLD-associated advanced liver disease reflects both the
Publikováno v:
Journal of Hepatology. 68:550-562
Liver disease remains a leading cause of mortality worldwide despite recent successes in the field of viral hepatitis, because increases in alcohol consumption and obesity are fuelling an epidemic of chronic fatty liver disease for which there are cu